Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Siemens AG—and that’s Siemens Siemens, not Siemens Healthineers—is expanding its industrial software business further into ...

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

The cuts impact more than $2.4 billion in grant money, including $1.3 billion in grant funds already spent on projects ...

Tesla CEO Elon Musk is expected to step down from his position helming the federal Department of Government Efficiency (DOGE) ...

FDA Chief Medical Officer Hilary Marston, M.D., is leaving her position at the agency.  | The FDA’s Chief Medical Officer ...

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses ...

The Trump administration is halting research funding to Princeton University and reviewing about $9 billion in federal grants ...